Jw
Business Services · China · 398 Employees
View Company Info for Free
About
Headquarters
Building B Ke Rd Fl 5 No 699, Zhongwu, Chongqin...Phone Number
+86 2150783699Website
www.jwtherapeutics.comRevenue
$23.9 MillionIndustry
Most Recent Scoops
Highlights
$190M
Total Funding Amount
$100M
Most Recent Funding Amount
2
Number of Funding Rounds
Who is Jw
Jw Org Chart
Is Jw your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Jw
Check if Jw has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Jw launches new products
Earning: See what the market has to say on Jw recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Jw, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Jw has new funding data
Click to see if Jw had a recent Job posting/layoffs
Check out if Jw is spiking on competitors!
Recommended Actions
Find VP level buyers at Jw
Find 3 more new buyers
Jw financials insights
Gather financial insights about Jw, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Jw Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Jw Tech Stack
A closer look at the technologies used by Jw
Most Recent Scoops
Jw News & Media
JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva® in Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma
SHANGHAI, Aug. 27, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has approved the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection) for thePreliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress
SHANGHAI, May 30, 2024 /PRNewswire/ -- JW (Cayman) Therapeutics Co. Ltd (the "Company" or "JW Therapeutics", together with its subsidiaries, the "Group"), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the preliminary clinical data on relmacabtagene autoleucel ("relma-cel") injection in adults with active systemic lupus erythematosus ("SLE") in China at the 2024 European Alliance of AssociationsJW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma
SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China accepted the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection) for the treaJW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy
SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce an exclusive collaboration with 2seventy bio (NASDAQ: TSVT), for the co-development and commercialization of a chimeric antigen receptor (CAR) T-cell therapy product for autoimmune diseases (AID program) in Greater China. Pursuant to the collaboration agreement, JW Therapeu
Frequently Asked Questions Regarding Jw
JW Therapeutics (HKEx: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Founded in 2016, JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The company has built a top world-class platform for technology and product d... Read More